EMPEROR_HFrEF (Completed)
A phase III randomized, double-blind trial to evaluate efficacy and
safety of once daily empagliflozin 10 mg compared to placebo, in
patients with reduced Ejection Fraction (HFrEF).
- Medicine
- empagliflozin
- Population
- Heart failure
- Phase
- III
- Starting year
- 2016
- More information
- ClinicalTrials.gov